Entries by Peggy Bickerton

NCCN Announces Projects to Study Oral Decitabine and Cedazuridine in Collaboration with Taiho Oncology

For Immediate Release: April 14, 2021Media Contact:Rachel Darwin267-622-6624darwin@nccn.org NCCN Oncology Research Program to oversee projects exploring oral medication combination targeting tumor suppression genes. PLYMOUTH MEETING, PA [April 14, 2021] — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that three projects have been selected to study oral decitabine (35 mg) and […]

Astex Pharmaceuticals expands clinical evaluation of oral decitabine and cedazuridine tablets through new Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI)

NCI has announced availability to investigators of oral decitabine and cedazuridine tablets for clinical and nonclinical study proposals under the CRADA The collaboration is intended to study oral decitabine and cedazuridine tablets in a range of tumor types   Pleasanton, CA, – October 28th, 2020. ­­– Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka […]